Diabetes changed gene activity in mouse kidneys earlier and more strongly than in the heart, according to a 2026 Frontiers in Endocrinology study of 38 samples. Researchers found 74 time-linked genes in the kidney, many involved in inflammation and metabolism, and a gene called Enpp2 rose in damaged kidney cells.
According to research reviewed by Gram, a 2026 study in Frontiers in Endocrinology tracked how diabetes changes gene activity in the heart and kidneys of mice over time. Gram Research analysis of the findings suggests the kidneys changed sooner and more strongly than the heart. Researchers identified 74 genes in the kidney whose activity shifted steadily as diabetes progressed, many linked to inflammation and how the body processes fuel. One gene, Enpp2, appeared to rise in kidney cells that were already damaged. Insulin treatment reversed some early immune changes, and a separate set of kidney data hinted that an SGLT2 inhibitor diabetes drug might lower Enpp2 as well. These results come from animal research and are preliminary, so they generate ideas for future human studies rather than offering treatment advice.
Key Statistics
A 2026 study in Frontiers in Endocrinology tracked 38 heart and kidney tissue samples from mice across six bi-weekly time points and found that kidney gene activity changed earlier and more strongly than heart gene activity under diabetic conditions.
In the same 2026 mouse research, scientists identified 74 core genes in the kidney whose activity shifted over time during diabetes, with many linked to immune and metabolic pathways.
A 2026 analysis that combined bulk tissue data with single-cell data from 16 mouse kidneys reported higher levels of the gene Enpp2 in injured proximal tubule cells in diabetic kidney disease.
The Quick Take
- What they studied: Researchers wanted to know how diabetes changes the way genes switch on and off in the heart and kidneys over time, and whether those changes differ between the two organs.
- Who participated: The main experiment used 38 tissue samples from laboratory mice, grouped into healthy controls, mice fed a high-fat diet, mice with diabetes, and diabetic mice treated with insulin. Samples were collected every two weeks across six time points. A second, separate dataset from 16 mouse kidneys was also analyzed.
- Key finding: The kidney showed bigger and earlier gene activity changes than the heart in diabetic mice. Researchers found 74 kidney genes whose activity shifted over time, and a gene called Enpp2 was higher in damaged kidney cells. These are exploratory results, so they point toward possibilities rather than proven effects.
- What it means for you: This study does not show that any food, supplement, or app habit changes diabetes outcomes in people. It does highlight the kidneys as an organ that may respond early to diabetes, which is one reason regular blood sugar, blood pressure, and kidney checks are worth discussing with a doctor.
The Research Details
The researchers followed mice over time, collecting heart and kidney tissue every two weeks across six sampling points. By taking many samples over time, they could see how gene activity changed gradually rather than just comparing a single snapshot. Tissue samples were tested to measure which genes were turned up or down in each group.
To get more detail about specific cell types, the team also combined their results with a separate public dataset that examined individual kidney cells from 16 mice. This dataset included healthy mice, mice with diabetic kidney disease, and mice treated with an SGLT2 inhibitor, a type of diabetes medicine. Looking at single cells helped show which cell types were driving the changes.
The team used statistical tools to find patterns, group genes that moved together, and check whether results from the two datasets overlapped. Key findings were then confirmed using additional lab tests on the tissue.
Tracking the same animals across several weeks shows the order in which changes happen, which a single measurement cannot reveal. Comparing heart and kidney side by side helps show which organ is affected first and most. Pairing bulk tissue results with single-cell data helps link a pattern to the specific cells where it is happening, making the findings more useful for generating future hypotheses.
The study used a careful, repeated sampling design and confirmed some findings with separate laboratory tests, which are strengths. However, it is labeled as exploratory and hypothesis-generating, meaning the authors themselves describe the results as a starting point. The sample is small, it uses mice rather than people, and the single-cell data came from a different group of animals treated with a different drug, so direct comparisons are limited.
What the Results Show
The clearest result was that diabetes changed gene activity in the kidney more strongly and earlier than in the heart. When researchers compared the groups, the kidney samples separated from healthy controls sooner, suggesting it responds to diabetes before the heart does.
Using a statistical method designed for changes over time, the team identified 74 core genes in the kidney whose activity shifted as diabetes developed. Many of these genes clustered into a major group tied to immune activity and metabolism, which are the systems that handle inflammation and how the body uses energy. This suggests that inflammation and fuel processing are closely tangled up in early diabetic kidney changes.
The single-cell data pointed to a specific cell type. Enpp2 was increased in injured proximal tubule cells, the cells in the kidney that help filter the blood and reabsorb useful substances. Meanwhile, two immune-related genes, H2-K1 and H2-D1, were lower in immune cells. Several hub genes overlapped between the bulk tissue and single-cell datasets, which strengthens confidence that these patterns are real rather than random noise.
Insulin treatment appeared to reverse some of the whole-body metabolic changes and early immune changes in the main mouse group. The SGLT2 inhibitor data were less direct, but they suggested that this drug may also lower Enpp2 in injured kidney cells. The authors describe this parallel as a hypothesis to test, not a confirmed effect.
The study also reported that diabetic and high-fat diet mice showed broad shifts in metabolic and inflammatory gene activity compared with healthy controls. These shifts were the backdrop for the more specific kidney findings. Confirmation through separate lab methods, including qPCR and immunohistochemistry, supported that the key genes were measured accurately, although these tests are technical checks rather than proof of health outcomes. The idea that Enpp2 may be a shared target of two different treatments is the most intriguing secondary point, but it remains speculative until tested directly.
Previous research has widely linked diabetes with kidney inflammation and changes in immune and metabolic activity, so the broad direction of these findings is consistent with what scientists already know. What appears newer is the time-based comparison showing the kidney changes earlier than the heart, and the identification of Enpp2 in injured proximal tubule cells as a possible marker to study. Because this is a single exploratory study, it adds a useful lead rather than settling any question.
The study used mice, and mouse biology does not always match human biology, so results may not translate directly to people. The sample size was modest, with 38 bulk samples and 16 single-cell kidney samples. The single-cell dataset came from a different experiment, with different animals and a different treatment, so the authors could not directly compare the two interventions. The researchers themselves describe the work as exploratory, meaning findings need larger and more targeted studies before anyone can draw firm conclusions about Enpp2 or any drug.
The Bottom Line
Confidence in the broad idea that diabetes affects the kidney early and that inflammation and metabolism are involved is moderate, since it agrees with earlier research. Confidence that Enpp2 is a reliable target, or that SGLT2 inhibitors act through it, is low at this stage because the evidence is preliminary and comes from animals. For now, the practical takeaway is to keep kidney health on your radar by discussing regular kidney function tests with your healthcare provider if you have diabetes.
People living with diabetes, their families, and clinicians who follow diabetic kidney disease may find this research interesting as a direction for future work. Researchers studying kidney biology and diabetes medicines will likely find the gene targets useful. People without diabetes or kidney concerns should not change their habits based on this study alone. Anyone considering a diabetes medicine or supplement should talk with a doctor first.
Findings from an animal exploratory study typically take years of follow-up research before they affect clinical care. Any future human tests of Enpp2 as a marker or drug target would likely require several years of laboratory work and clinical trials. Individuals managing diabetes can see changes in kidney health markers over months, which is why routine checks are useful.
Frequently Asked Questions
Does diabetes affect the kidneys before the heart?
In a 2026 mouse study in Frontiers in Endocrinology, gene activity changes appeared earlier and were stronger in the kidney than in the heart. This suggests the kidney may respond to diabetes sooner, but the research was done in animals and needs confirmation in human studies.
What is the Enpp2 gene and why does it matter in diabetic kidney disease?
Enpp2 was higher in injured proximal tubule cells, the kidney cells that filter blood, in a mouse study of diabetic kidney disease. Researchers see it as a possible marker to study, but its role in people with diabetes has not yet been established by research.
Can insulin reverse early immune changes caused by diabetes in mice?
A 2026 study reported that insulin treatment reversed some systemic metabolic and early immune changes in diabetic mice. The findings were exploratory, based on 38 tissue samples, so they indicate a partial effect that requires further testing.
Do SGLT2 inhibitors lower Enpp2 in kidney cells?
A separate single-cell dataset from 16 mouse kidneys suggested that SGLT2 inhibitors may lower Enpp2 in injured kidney cells. This is a hypothesis generated by the study, not a confirmed effect, and direct comparative research is needed.
Want to Apply This Research?
- If you have diabetes or are at risk, track fasting blood sugar and blood pressure readings a few times per week, and log the date of your most recent kidney function test (such as eGFR or urine albumin) so you can see trends over time.
- Use the app to set a weekly reminder to schedule or confirm your routine kidney and blood sugar checks with your healthcare provider. Pair this with logging daily fluid intake and sodium-heavy meals, as these habits are commonly discussed in kidney health guidance, though this study does not directly test them.
- Review your logged blood sugar, blood pressure, and lab results every three months with your care team. Look for steady trends rather than single readings, and share the summary at each appointment so changes can be caught early.
This article summarizes an exploratory study conducted in mice and published in Frontiers in Endocrinology. Animal findings do not always apply to people, and the results described here are preliminary. This content is for general education only and is not medical advice. If you have diabetes or kidney concerns, talk with your healthcare provider before changing your diet, medicines, or treatment plan.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.